All Posts

New campaign tackles diabetes complications: Are You At Risk?

Neuropathy is a serious and sometimes overlooked problem for patients with diabetes. The American Diabetes Associations estimates that 60-70% of diabetics have mild to severe nervous system damage. Learn how drug manufacturer Shire is educating everyone about a new risk assesment tool in addition to complications associated with having diabetes. Learn more.

Teplizumab benefits type 1 diabetes patients in midstage study

Type 1 diabetes patients who were on teplizumab, an experimental treatment, were able to maintain their insulin production rates for two years, longer than patients on most other diabetes medications, according to data from a Phase II study published in Diabetes. However, about half of patients did not benefit from the drug. Researchers said patients who saw the most benefit were those who still had good glucose control and moderate insulin requirements at the start of the study.

Back To School With Diabetes

Sending a student with diabetes back to school, whether it is the first time after a new diagnosis, or the start of a new school year, requires careful planning and coordination. Getting a diabetes medical management plan in place is the first place to start. Check out our Diabetes at School page to learn more about resources available to you.

See Dr. Atkinson featured in the new UF Health ad campaign

UF&Shands, the University of Florida Academic Health Center, is now University of Florida Health. The new umbrella term reflects the health system's strong ties to UF, a key part of what differentiates the academic health center — with its focus on excellence in research, teaching and patient care — from its competitors. See how invisible connections are making a difference in the lives of every patient we serve.

Making Insulin: Producing a lifesaving medication

Today, the insulin that comes in vials, pens, and pumps is not from pigs and cows but from pharmaceutical companies armed with the latest groundbreaking biotechnology. Join Diabetes Forecast Magazine for a behind-the-scenes look at the making of this lifesaving medication.

Technology Corner: WellDoc app now available

WellDoc has announced the launch of BlueStar, an FDA approved prescription version of its “Diabetes Manager” program. BlueStar is the first disease therapy system to be prescribed through an app. WellDoc was designed for people with type 2 diabetes. The goal of this new mobile technology is to educate patients about type 2 diabetes and keep them engaged in their disease management. WellDoc is the first app to be eligible for reimbursement. Learn more.

Autologous stem cells cut insulin requirements in T2DM

A study in Cell Transplantation found type 2 diabetes patients who received autologous bone marrow stem cells required lower insulin doses compared with those in the control group. Longer-duration studies with a larger number of participants will be needed to establish the efficacy of stem cell treatment in diabetes, researchers said. Read more.

Visit your local Walgreens and support JDRF!

From now through July 31st when you visit your local Walgreens, you can support JDRF by making a donation of $1, $2, $5, or $10 at checkout. The dollars raised through this campaign will help JDRF create a world without T1D. Walgreens has supported JDRF for 20 years, contributing more than $20 million to JDRF's mission. Visit today!

Legislation calls for exercise guidelines for Americans of all ages

A bipartisan U.S. House bill calls on HHS to create exercise guidelines for all Americans, based on scientific and medical knowledge, and update them every 10 years to promote healthy habits. The guidelines would include exercise recommendations for specific groups, such as children, and was submitted along with the FIT Kids Act, which would provide grant funding for school physical education and nutrition programs.